Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Probing C84-embedded Si Substrate Using Scanning Probe Microscopy and Molecular Dynamics

Probing C₈₄-embedded Si Substrate Using Scanning Probe Microscopy and Molecular Dynamics

Published on: September 28, 2016

A composite design for transition from a preliminary to a full-scale study.

John M Lachin¹, Naji Younes

¹The Biostatistics Center, Department of Epidemiology and Biostatistics, The George Washington University, 6110 Executive Boulevard, Suite 750, Rockville, MD 20852, USA. jml@biostat.bsc.gwu.edu

Statistics in Medicine

|June 20, 2007

Summary

This study introduces a combined Phase II to Phase III drug development design, reducing patient numbers and study duration. It optimizes statistical power and error probabilities for more efficient clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts.

Diabetes technology & therapeutics·2025

Same author

Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Diabetes care·2025

Same author

Common genetic variants near <i>SLC2A2</i> and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial.

medRxiv : the preprint server for health sciences·2025

Same author

Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.

Diabetes care·2025

Same author

Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial.

JAMA internal medicine·2025

Same author

Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.

Diabetes care·2025

Area of Science:

Clinical trial design
Drug development statistics

Background:

Traditional drug development involves sequential Phase II and Phase III studies.
This can lead to increased patient numbers and extended program durations.

Purpose of the Study:

To describe a combined preliminary (Phase II) to full-scale (Phase III) study design.
To demonstrate how this integrated approach can reduce overall patient requirements and program timelines.
To present a statistical framework for managing futility or safety stopping boundaries and maintaining desired error rates.

Main Methods:

The design integrates patients from a preliminary study into a subsequent full-scale study.
It utilizes a futility or safety stopping boundary with a lower critical Z-value (Z(L)) to manage early study termination.

More Related Videos

Generation of Scalable, Metallic High-Aspect Ratio Nanocomposites in a Biological Liquid Medium

Generation of Scalable, Metallic High-Aspect Ratio Nanocomposites in a Biological Liquid Medium

Published on: July 8, 2015

Related Experiment Videos

Last Updated: Jul 14, 2026

Probing C84-embedded Si Substrate Using Scanning Probe Microscopy and Molecular Dynamics

Probing C₈₄-embedded Si Substrate Using Scanning Probe Microscopy and Molecular Dynamics

Published on: September 28, 2016

Generation of Scalable, Metallic High-Aspect Ratio Nanocomposites in a Biological Liquid Medium

Generation of Scalable, Metallic High-Aspect Ratio Nanocomposites in a Biological Liquid Medium

Published on: July 8, 2015

Statistical methods involve large-sample normally distributed Z-tests for means, proportions, or survival times, allowing for combined or sequential testing across phases.

Main Results:

The combined design potentially reduces the total number of patients and overall study duration.
It allows for precise control of Type I and Type II error probabilities by determining appropriate sample sizes and critical values (Z(L) and Z(F)).
The design maintains the desired Type I error probability for the final test while incorporating early stopping rules.

Conclusions:

The combined preliminary to full-scale study design offers a more efficient approach to drug development.
It provides a statistically sound method for optimizing resource allocation and timelines in clinical trials.
Practical considerations for implementing this integrated design are discussed, highlighting its potential benefits for pharmaceutical research.